🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 3 of 55

  1. AG-013736

    Pfizer

    Thyroid Neoplasms

    phase 2 small molecule completed

    1 trial

  2. AG-120

    Agios Netherlands B.V.

    Chondrosarcoma

    phase 2 small molecule active

    1 trial

  3. AG-120/S95031 250mg film-coated tablet, IMFINZI 50 mg/mL concentrate for solution for infusion., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    The George Institute

    Locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation

    phase 2 small molecule active

    1 trial

  4. AK104

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. AK104

    Akeso

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  6. AK104, nab-paclitaxel, carboplatin

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  7. AK105 and anlotinib

    The First People's Hospital of Lianyungang

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  8. AK112

    Summit Therapeutics

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  9. AK112, Cadonilimab, nab-paclitaxel, gemcitabine

    Akeso

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  10. AK117

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  11. AL8326

    Lacuna Pharma Pty Ltd

    - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment., - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage. - Non Small Cell Lung Cancer (NSCLC) patients who need ≥2nd line treatment with brain metastasis which is controlled with no active hemorrhage. - Renal Cell Carcinoma (RCC) patients who need ≥2nd line treatment.

    phase 2 small molecule active

    1 trial

  12. AL8326

    Lacuna Pharma Pty Ltd

    Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage., Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

    phase 2 small molecule active

    1 trial

  13. ALDESLEUKIN , TIL cells

    Disc Medicine

    Ovarian carcinoma

    phase 2 small molecule active

    1 trial

  14. ALDESLEUKIN , Tumor Intiltrating Lymphocytes (TIL) – VHIO, FLUDARABINE , CYCLOPHOSPHAMIDE

    The George Institute

    Germ Cell Tumors refractory to salvage chemotherapy

    phase 2 small molecule active

    1 trial

  15. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  16. ALEXAN, 50 MG/ML, ROZTWÓR DO INFUZJI, Liposomal Annamycin

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  17. ALG.APV-527

    Aptevo Therapeutics

    Solid Tumor

    phase 2 small molecule active

    1 trial

  18. ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PDC*lung01, PDC*lung01

    Lacuna Pharma Pty Ltd

    Non-small-cell lung cancer

    phase 2 small molecule active

    1 trial

  19. ALLO-501A

    Allogene Therapeutics

    Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

    phase 2 gene therapy active

    1 trial

  20. ALLO-647

    Allogene Therapeutics

    Relapsed/Refractory Large B Cell Lymphoma

    phase 2 mab terminated

    1 trial

  21. ALPELISIB, FULVESTRANT, ALPELISIB, LETROZOLE, LEUPRORELIN ACETATE, GOSERELIN

    Novartis Pharmaceuticals

    Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer

    phase 2 small molecule active

    1 trial

  22. ALPELISIB, RIBOCICLIB, LETROZOLE, LEE011, ALPELISIB, LEE011

    Novartis Pharmaceuticals

    Advanced HR+ breast cancer

    phase 2 small molecule active

    1 trial

  23. AMG 193

    Amgen

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. AMG 193, AMG 193, AMG 193

    Amgen

    Advanced MTAP-null solid tumors

    phase 2 small molecule active

    1 trial

  25. AMG 193, IDE397, AMG 193, IDE397, AMG 193

    Amgen

    In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  26. AMG 706

    Takeda

    Advanced Gastrointestinal Stromal Tumor

    phase 2 small molecule completed

    1 trial

  27. APR-246

    Aprea Therapeutics

    Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

    phase 2 small molecule completed

    1 trial

  28. APR-246

    Aprea Therapeutics

    High-grade Serous Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  29. APR-246

    Aprea Therapeutics

    Melanoma

    phase 2 small molecule terminated

    1 trial

  30. APR-246

    Aprea Therapeutics

    Acute Myeloid Leukemia or Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  31. APR-246 (eprenetapopt) + Acalabrutinib in CLL

    Aprea Therapeutics

    Non Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

  32. APR-246 (eprenetapopt) + Pembrolizumab

    Aprea Therapeutics

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  33. APREPITANT, IDARUBICIN HYDROCHLORIDE, LEVOCARNITINE, CYCLOPHOSPHAMIDE, GRANISETRON, SALBUTAMOL, GANCICLOVIR, AMPHOTERICIN B, ALLOPURINOL, DARZALEX 1800 mg solution for injection, HUMAN FIBRINOGEN, CYTARABINE, DEXAMETHASONE SODIUM PHOSPHATE, VINCRISTINE SULFATE, PARACETAMOL, MONTELUKAST, FILGRASTIM, CYTARABINE, LEVOFLOXACIN, RASBURICASE, METHOTREXATE, HYDROCORTISONE, FOSCARNET, METHYLPREDNISOLONE SODIUM SUCCINATE, LENOGRASTIM, PEGASPARGASE, DEXAMETHASONE SODIUM PHOSPHATE, MICAFUNGIN, ACICLOVIR, CHLORPHENAMIN

    Fondazione Telethon ETS

    Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  34. APX005M

    Pyxis Oncology

    Melanoma

    phase 2 small molecule terminated

    1 trial

  35. ARI-0001, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    Disc Medicine

    relapsed/refractory Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  36. ART27.13, Placebo, ART27.13

    ARTELO BIOSCIENCES, INC.

    Cancer Anorexia

    phase 2 small molecule active

    1 trial

  37. ASCAPE-based follow-up strategy

    ATOSSA THERAPEUTICS, INC.

    Breast Cancer

    phase 2 other active

    1 trial

  38. ASCIMINIB, ASCIMINIB HYDROCHLORIDE, Asciminib

    Novartis Pharmaceuticals

    Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors

    phase 2 small molecule active

    1 trial

  39. ASLAN001

    Hospital Authority, Hong Kong

    Advanced/ Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  40. ASP1570, ASP1570, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Astellas Pharma GmbH

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  41. ASP3082, DEXTROSE INJECTION / BRADEX 5%

    The George Institute

    Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  42. ASP5541, ABIRATERONE ACETATE, PREDNISOLONE, PREDNISONE

    Astellas Pharma GmbH

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  43. ASP8273

    Astellas Pharma Inc

    Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  44. ASP8951, Calcium Folinate 10 mg/ml Injection, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Fluorouracil 50mg/ml Injection., OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.

    Astellas Pharma GmbH

    Advanced cancer of the stomach or the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  45. ASP8951, PACLITAXEL, GEMCITABINE

    Astellas Pharma GmbH

    First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.

    phase 2 small molecule active

    1 trial

  46. ASTX727

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors

    phase 2 small molecule active

    1 trial

  47. ASTX727, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets

    Taiho Pharma Netherlands B.V.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  48. ATEZOLIZUMAB

    The George Institute

    Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.